Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori Eradication
| Autor: | Kusunoki Maho, Yuki Mika, Ishitobi Hitomi, Kobayashi Yoshiya, Nagaoka Makoto, Takahashi Yoshiko, Fukuba Nobuhiko, Komazawa Yoshinori, Shizuku Toshihiro, Kinoshita, Yoshikazu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male potassium-competitive acid blockers macromolecular substances Helicobacter pylori eradication elderly atrophic gastritis second-line therapy Helicobacter Infections Clarithromycin Metronidazole Odds Ratio Humans Pyrroles Aged Retrospective Studies Sulfonamides Age Factors Amoxicillin Proton Pump Inhibitors Middle Aged Anti-Bacterial Agents Treatment Outcome Gastric Mucosa Original Article Drug Therapy Combination Female Atrophy |
| Zdroj: | Internal Medicine |
| ISSN: | 1349-7235 0918-2918 |
| Popis: | Objective We evaluated the efficacy of vonoprazan-based eradication therapy for Helicobacter pylori (H. pylori), including the effects of age, gender, and grade of atrophy in comparison to proton pump inhibitor-based therapy. Method We retrospectively reviewed the records of 1,172 patients who received first-line triple therapy with amoxicillin, clarithromycin, and vonoprazan or a proton pump inhibitor (PPI) for H. pylori eradication, as well as 157 patients treated with second-line therapy consisting of amoxicillin, metronidazole, and vonoprazan or a PPI. Results The eradication rate of all cases treated with first-line triple therapy was 86.9% (1,019/1,172), while that in those treated with vonoprazan-based therapy was 92.5% (384/415). Our analysis showed that the use of vonoprazan resulted in a significantly improved success rate of first-line eradication therapy in comparison to proton pump inhibitor-based therapy [odds ratio (OR), 2.36; 95% confidence interval (CI) 1.55 to 3.56]. The superiority of vonoprazan was remarkable in non-elderly patients, while its effect was unclear in elderly patients. When used as second-line eradication therapy, the advantage of vonoprazan over PPI administration was not clear. Conclusion The inclusion of vonoprazan increased the success rate of first-line eradication therapy; however, the advantage was reduced with aging and remained unclear in elderly patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|